Enovis Announces Third Quarter 2025 Results

Core Insights - Enovis Corporation reported a third-quarter net sales of $549 million, reflecting a 9% increase on a reported basis and a 7% increase on an organic basis compared to the same quarter in 2024 [2][14] - The company experienced a net loss of $571 million, primarily due to a non-cash goodwill impairment charge of $548 million, which does not affect future operations [3][4] - Enovis updated its 2025 financial outlook, projecting revenue between $2.24 billion and $2.27 billion and adjusted EBITDA between $395 million and $405 million [5] Financial Performance - Third-quarter net sales reached $549 million, with Recon sales growing 12% and P&R sales growing 6% year-over-year [2][14] - The adjusted EBITDA for the third quarter was $95 million, representing a margin of 17.3% [3][12] - The adjusted net earnings per diluted share were reported at $0.75, while the net loss per share was $9.99 [4][20] Strategic Focus - The company is concentrating on commercial execution, innovation, operational excellence, and financial discipline to drive profitable growth [5][6] - Enovis completed the divestiture of its Diabetic Footcare business unit for total proceeds of up to $60 million, which contributed to the revenue reduction in the updated guidance [5][14] Market Position - Enovis is positioned as an innovation-driven medical technology growth company, focusing on enhancing patient outcomes and operational efficiency for healthcare providers [7][8] - The company aims to leverage its diversified growth platform to maintain momentum in new product introductions and stable end markets [2][14]